Top Page
Mayne Pharma Group
(OTC:MYX)
Mayne Pharma Group (MYX) vs. iShares MSCI Australia ETF (EWA)
Mayne Pharma Group Business Overview & Revenue Model
Mayne Pharma Group Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 408.10M | 408.10M | 388.15M | 183.59M | 157.15M | 400.78M |
| Gross Profit | 247.27M | 247.27M | 218.53M | 26.84M | 23.75M | 127.02M |
| EBITDA | 42.08M | 42.08M | -116.93M | -193.80M | -78.88M | -182.40M |
| Net Income | -93.84M | -93.84M | -174.23M | 117.25M | -281.29M | -208.42M |
Balance Sheet | ||||||
| Total Assets | 1.01B | 1.01B | 1.14B | 1.25B | 1.30B | 1.48B |
| Cash, Cash Equivalents and Short-Term Investments | 100.40M | 100.40M | 149.28M | 220.14M | 97.08M | 98.35M |
| Total Debt | 41.27M | 41.27M | 38.82M | 47.51M | 413.67M | 346.82M |
| Total Liabilities | 644.32M | 644.32M | 688.99M | 613.77M | 764.89M | 706.56M |
| Stockholders Equity | 370.28M | 370.28M | 454.19M | 634.36M | 545.88M | 768.36M |
Cash Flow | ||||||
| Free Cash Flow | 5.19M | 5.19M | -36.16M | -262.71M | -28.47M | 22.16M |
| Operating Cash Flow | 17.47M | 17.47M | -15.30M | -43.12M | -16.62M | 47.26M |
| Investing Cash Flow | -68.07M | -68.07M | 53.45M | 473.49M | -28.53M | -49.25M |
| Financing Cash Flow | -4.00M | -556.00K | -19.85M | -431.48M | 27.60M | -28.83M |
Mayne Pharma Group Technical Analysis
Mayne Pharma Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$393.02M | 25.03 | 22.84% | 0.87% | 21.47% | 89.09% | |
53 Neutral | AU$1.16B | -15.32 | -54.37% | ― | ― | -29.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$110.58M | -8.11 | -31.98% | ― | 34.20% | -23.90% | |
49 Neutral | AU$552.65M | -8.77 | -35.86% | ― | ― | -19.21% | |
47 Neutral | AU$360.24M | -25.42 | -83.97% | ― | 1271.12% | 36.87% | |
38 Underperform | AU$264.05M | -2.78 | -21.13% | ― | 5.07% | 46.14% |
Mayne Pharma Group Corporate Events
Mayne Pharma Group Limited has issued a notice of intention to terminate the Scheme Implementation Deed with Cosette Pharmaceuticals due to material breaches by Cosette. These breaches include failing to meet obligations related to FIRB approval and debt financing, which could impact the proposed acquisition. Mayne Pharma reserves the right to terminate the agreement if the breaches are not resolved within five business days, potentially affecting its strategic plans and stakeholder interests.
Mayne Pharma Group announced that its proposed acquisition by Cosette Pharmaceuticals is unlikely to proceed due to the objection from the Foreign Investment Review Board (FIRB). The scheduled court hearing has been vacated, and Mayne Pharma is assessing its options and next steps while consulting with Cosette on available alternatives. This development impacts the company’s strategic plans and may affect stakeholders’ expectations.
Mayne Pharma Group Limited has requested a trading halt on its securities pending a significant announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move indicates a strategic shift that could potentially impact the company’s market positioning and stakeholder interests.
Mayne Pharma has announced an update on its proposed acquisition by Cosette Pharmaceuticals, with the Foreign Investment Review Board extending its approval deadline to November 21, 2025. The company has rescheduled the court hearing to approve the scheme of arrangement to November 23, 2025. The acquisition remains contingent on FIRB and court approvals, among other conditions. If approved, Mayne Pharma shares will be suspended from trading on November 24, 2025, marking a significant shift in its market presence.
The Panel declared unacceptable circumstances in Mayne Pharma’s dealings with Cosette Pharmaceuticals, Inc., following Cosette’s change of intentions regarding the Salisbury Site. This decision impacts the market’s perception of the control over Mayne Pharma, highlighting concerns about competitive and informed market principles. The Panel’s orders require Cosette to comply with conditions related to the Salisbury Site, ensuring transparency and adherence to initial disclosures.
Mayne Pharma Group Limited is navigating the approval process for its acquisition by Cosette Pharmaceuticals, which is contingent on the Foreign Investment Review Board’s (FIRB) decision. The FIRB has extended its decision deadline to 20 November 2025, and Cosette’s current debt arrangements are only available if the scheme becomes effective by 24 November 2025. The scheme’s progression is not dependent on Cosette’s current debt facilities, and Mayne Pharma is committed to enforcing its rights under the Scheme Implementation Deed. The company is closely monitoring the situation as the Second Court Hearing is scheduled for 21 November 2025, which will determine the scheme’s effectiveness by the new deadline.
Mayne Pharma Group Limited has initiated proceedings with the Takeovers Panel regarding its affairs, specifically concerning the Scheme Implementation Deed with Cosette Pharmaceuticals, Inc. The Panel has issued interim orders to amend the End Date in the Deed to 24 November 2025, preventing Cosette from terminating the agreement without prior consent. This action aims to maintain the status quo while the Panel considers the application, impacting the ongoing merger process between Mayne and Cosette.
Mayne Pharma Group Limited has requested a trading halt on its securities pending the release of a material announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move is expected to have significant implications for the company’s operations and market positioning, as it could potentially lead to strategic realignment and impact stakeholders involved.
Mayne Pharma Group Limited announced an update regarding its proposed acquisition by Cosette Pharmaceuticals, with the Foreign Investment Review Board extending the statutory deadline for approval to 17 November 2025. The acquisition scheme remains contingent on FIRB and court approvals, among other conditions, but the indicative timetable remains unchanged. Shareholders are advised that no action is required from them at this time.
The FDA’s decision to remove the ‘black box’ warnings from hormone replacement therapies (HRTs) marks a significant regulatory change that is expected to enhance prescribing practices, boost patient and physician confidence, and expand the market for women’s health therapies. This change could reduce stigma and hesitation around HRT, potentially unlocking new patient segments and increasing the utilization of Mayne Pharma’s HRT products, BIJUVA® and IMVEXXY®, thereby driving commercial execution and delivering greater value for patients.
Mayne Pharma Group Limited is currently involved in legal proceedings with Cosette Pharmaceuticals regarding a proposed acquisition scheme. The Supreme Court of New South Wales ruled in favor of Mayne Pharma, dismissing Cosette’s claims, but Cosette has filed a notice of intention to appeal. Mayne Pharma is taking steps to implement the acquisition scheme, which remains subject to certain conditions, including court and regulatory approvals. The company is also considering measures to expedite the appeal process and will update the market on any changes to the acquisition timeline.
Mayne Pharma Group Limited has received an extension from the Australian Securities and Investments Commission to delay its 2025 Annual General Meeting until January 2026. This extension aligns with the anticipated timeline for the company’s acquisition by Cosette Pharmaceuticals, contingent on fulfilling certain conditions, including FIRB and Court approvals. If the acquisition proceeds as planned, Mayne Pharma will not need to hold an AGM as it will have only one shareholder. The outcome of this acquisition could significantly impact Mayne Pharma’s operational structure and market positioning.
Mayne Pharma Group announced that the Foreign Investment Review Board (FIRB) has extended the deadline for approval of its acquisition by Cosette Pharmaceuticals to 14 November 2025. The acquisition, structured as a scheme of arrangement, still requires FIRB and court approvals. If approved, Mayne Pharma shares will be suspended from trading on 19 November 2025, with the scheme implementation date set for 1 December 2025. The extension may impact the timeline of the acquisition, but Mayne Pharma will keep stakeholders informed of any changes.
Mayne Pharma Group Limited has submitted an application to the Panel regarding its affairs, following a series of events related to its acquisition by Cosette Pharmaceuticals, Inc. The acquisition, valued at $7.40 per share, faced challenges including allegations of a Material Adverse Change and issues with continuous disclosure obligations. Despite these challenges, the NSW Supreme Court ruled in favor of Mayne, invalidating Cosette’s termination notices. However, the acquisition’s future remains uncertain as the Treasurer expressed concerns that it may negatively impact the Australian economy and community, potentially affecting the national interest.
Mayne Pharma Group Limited has announced updates regarding the Foreign Investment Review Board (FIRB) approval and the proposed scheme of arrangement for Cosette Australia BidCo Pty Ltd to acquire all shares in the company. The Supreme Court of New South Wales has rescheduled the hearing to approve this scheme to 18 November 2025, pending FIRB approval. The FIRB has extended its statutory deadline, and if approval is received before 14 November 2025, Mayne Pharma may request an earlier court date. Shareholders have the right to oppose the scheme at the court hearing, which is crucial for the acquisition process and could significantly impact Mayne Pharma’s future operations and market positioning.
Mayne Pharma Group Limited is facing potential challenges in its proposed acquisition by Cosette Pharmaceuticals, as the Australian Treasurer has expressed preliminary concerns that the acquisition may not be in the national interest due to potential negative impacts on the Australian economy and community. The Treasurer is particularly concerned about the potential closure of Mayne Pharma’s manufacturing site in Adelaide, which plays a significant role in Australia’s pharmaceutical manufacturing and research capabilities. Mayne Pharma has invested heavily in this site and disagrees with the commercial rationale for its closure. The company is actively engaging with Cosette to address these concerns and expedite the approval process, while also keeping shareholders informed of developments.
Mayne Pharma Group Limited has announced the cessation of 5,503 performance rights due to unmet conditions, as of October 28, 2025. This announcement may impact the company’s operational strategy and stakeholder interests, reflecting a potential shift in how performance incentives are managed within the organization.
UBS Group AG and its related bodies corporate have ceased to be substantial shareholders of Mayne Pharma Group Limited as of October 16, 2025. This change in shareholder status may impact Mayne Pharma’s market dynamics and investor relations, as substantial shareholders often have significant influence over company decisions.
Mayne Pharma Group Limited announced the cessation of 8,311 performance rights due to the lapse of conditional rights that were not satisfied. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s performance and strategic goals.
Mayne Pharma Group Limited announced a delay in the Foreign Investment Review Board’s decision regarding its acquisition by Cosette Pharmaceuticals, which may affect the timing of the Second Court Hearing initially scheduled for 22 October 2025. The company is assessing whether to reschedule the hearing and will update stakeholders accordingly, though shareholders are not required to take any action at this time.
Mayne Pharma Group Limited has announced a court hearing to approve a proposed scheme of arrangement, where Cosette Australia BidCo Pty Ltd will acquire 100% of Mayne Pharma’s shares. This follows the approval of the scheme by Mayne Pharma shareholders in June 2025. The hearing is scheduled for October 22, 2025, at the Supreme Court of New South Wales. Shareholders have the right to appear and oppose the scheme if desired. This acquisition could significantly impact Mayne Pharma’s operations and market positioning, potentially affecting stakeholders involved.
Mayne Pharma Group Limited has announced a favorable outcome in its legal proceedings with Cosette Pharmaceuticals, Inc., regarding the proposed acquisition by Cosette. The Supreme Court of New South Wales ruled in favor of Mayne Pharma, dismissing Cosette’s claims. The company will proceed with the acquisition scheme, which is subject to certain conditions, including FIRB and court approvals. The scheme is expected to become effective on 23 October 2025, with shareholders receiving $7.40 per share on or around 3 November 2025. This development marks a significant step forward in Mayne Pharma’s strategic acquisition plans, potentially enhancing its market position and shareholder value.
Mayne Pharma’s Annual Report for 2025 highlights the company’s dedication to enhancing patient access to medications through innovation and accessibility. This commitment is expected to strengthen their market position and positively impact stakeholders by ensuring the availability of better and safer medicines.
Mayne Pharma Group has released its 2025 Corporate Governance Statement, emphasizing its adherence to the ASX Corporate Governance Principles and Recommendations. The Board of Directors is committed to guiding the company with a focus on shareholder interests, risk management, and ethical conduct. The statement highlights the company’s comprehensive governance policies, including a Business Code of Conduct and various committee charters, which are available on its website. This release underscores Mayne Pharma’s dedication to updating its governance practices in line with evolving standards, potentially strengthening its industry position and stakeholder trust.
Mayne Pharma Group Limited announced the cessation of certain securities, specifically 529,129 performance rights and 695,322 options, due to the expiry of options or other convertible securities without exercise or conversion as of September 30, 2025. This cessation may impact the company’s capital structure and could have implications for stakeholders, as it reflects adjustments in the company’s financial instruments and potential changes in shareholder value.
Mayne Pharma announced that its oral contraceptive, NEXTSTELLIS®, has been approved for reimbursement by the Australian Pharmaceutical Benefits Scheme (PBS), effective from October 1, 2025. This listing is expected to enhance access to contraceptive options in Australia, aligning with recommendations to improve access to newer hormonal contraceptives. NEXTSTELLIS® is notable for being the first contraceptive pill containing estetrol (E4), a natural estrogen, derived from a plant source. The PBS listing significantly reduces the cost for patients, making it more affordable and accessible, which is a positive development for women’s healthcare in Australia.
Mayne Pharma Group has announced that First Sentier Investors (Australia) IM Ltd has ceased to be a substantial holder in the company as of September 23, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market perception, as substantial holders often play a significant role in corporate governance and strategic decisions.
Mayne Pharma addresses recent media reports concerning objections to its Scheme transaction with Cosette, particularly regarding the potential closure of its Salisbury manufacturing site. The company clarifies that it has no plans to close the site and highlights its recent financial performance and facility upgrades. Mayne Pharma is seeking further information and considering direct communication with the Foreign Investment Review Board (FIRB) to ensure all necessary information is available for informed decision-making regarding the Scheme.